Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J. Clin. Oncol., 26, 2139, 10.1200/JCO.2007.14.4956 Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 Cragg, 2008, Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic, J. Clin. Invest., 118, 3651, 10.1172/JCI35437 Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat. Med., 14, 1351, 10.1038/nm.1890 Faber, 2009, Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition, Proc. Natl. Acad. Sci. USA, 106, 19503, 10.1073/pnas.0905056106 Garnett, 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, 483, 570, 10.1038/nature11005 Infante, 2010, Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212, J. Clin. Oncol., 28, 15s, 10.1200/jco.2010.28.15_suppl.2503 Jackson, 2001, Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras, Genes Dev., 15, 3243, 10.1101/gad.943001 Konopleva, 2006, Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, Cancer Cell, 10, 375, 10.1016/j.ccr.2006.10.006 Kumar, 2012, The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer, Cell, 149, 642, 10.1016/j.cell.2012.02.059 Ley, 2003, Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim, J. Biol. Chem., 278, 18811, 10.1074/jbc.M301010200 LoRusso, 2012, A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors, J. Clin. Oncol., 30, 10.1200/jco.2012.30.15_suppl.2566 Luo, 2009, A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene, Cell, 137, 835, 10.1016/j.cell.2009.05.006 Malumbres, 2003, RAS oncogenes: the first 30 years, Nat. Rev. Cancer, 3, 459, 10.1038/nrc1097 Milella, 2002, Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia, Blood, 99, 3461, 10.1182/blood.V99.9.3461 Montagut, 2009, Targeting the RAF-MEK-ERK pathway in cancer therapy, Cancer Lett., 283, 125, 10.1016/j.canlet.2009.01.022 Muranen, 2012, Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells, Cancer Cell, 21, 227, 10.1016/j.ccr.2011.12.024 Rahmani, 2009, The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways, Blood, 114, 4507, 10.1182/blood-2008-09-177881 Scholl, 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells, Cell, 137, 821, 10.1016/j.cell.2009.03.017 She, 2010, 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors, Cancer Cell, 18, 39, 10.1016/j.ccr.2010.05.023 Singh, 2009, A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 Singh, 2012, TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers, Cell, 148, 639, 10.1016/j.cell.2011.12.033 Speranza, 2012, Pharmacodynamic biomarker-driven trial of MK-2206, and AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma, J. Clin. Oncol., 30, 10.1200/jco.2012.30.15_suppl.3529 Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, 15545, 10.1073/pnas.0506580102 Taube, 2010, Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes, Proc. Natl. Acad. Sci. USA, 107, 15449, 10.1073/pnas.1004900107 Tse, 2008, ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor, Cancer Res., 68, 3421, 10.1158/0008-5472.CAN-07-5836 Willis, 2007, Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak, Science, 315, 856, 10.1126/science.1133289 Young, 2009, Ras signaling and therapies, Adv. Cancer Res., 102, 1, 10.1016/S0065-230X(09)02001-6